180 related articles for article (PubMed ID: 36294464)
1. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
[TBL] [Abstract][Full Text] [Related]
2. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
[TBL] [Abstract][Full Text] [Related]
3. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
4. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
[TBL] [Abstract][Full Text] [Related]
5. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
6. The Reevaluation of Thrombin Time Using a Clot Waveform Analysis.
Wada H; Ichikawa Y; Ezaki M; Matsumoto T; Yamashita Y; Shiraki K; Shimaoka M; Shimpo H
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768360
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
9. Clot Waveform Analysis for Hemostatic Abnormalities.
Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of emicizumab on activated clotting time in blood samples from cardiac surgical patients.
Tanaka KA; Henderson R; Thangaraju K; Morita Y; Mazzeffi MA; Strauss E; Katneni U; Buehler PW
Haemophilia; 2022 Jan; 28(1):183-190. PubMed ID: 34735039
[TBL] [Abstract][Full Text] [Related]
12. Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab.
Pfrepper C; Klamroth R; Ettingshausen CE; Petros S; Siegemund A; Siegemund T
Haemophilia; 2024 Mar; 30(2):545-553. PubMed ID: 38343119
[TBL] [Abstract][Full Text] [Related]
13. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
14. Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis.
Kato K; Hatayama Y; Shimohiro H; Ichikawa H; Fukuda T
Yonago Acta Med; 2022 Aug; 65(3):226-230. PubMed ID: 36061578
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
16. The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Sakano Y; Nishii H; Shimaoka M
Clin Appl Thromb Hemost; 2021; 27():1076029620976913. PubMed ID: 33606948
[TBL] [Abstract][Full Text] [Related]
17. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
18. Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time-based clotting time test results in patients treated with emicizumab.
Novembrino C; Boscolo-Anzoletti M; Galbiati E; Shinohara S; Peyvandi F
Res Pract Thromb Haemost; 2023 Nov; 7(8):102260. PubMed ID: 38193066
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
[TBL] [Abstract][Full Text] [Related]
20. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
